ALT-801
Pemvidutide[THERAPEUTIC_PROFILE]
Target Indications
MASH, AUD
Mechanism Abstract
A small molecule protein degrader
[3D_INTERACTIVE_CONFORMATION]
[CLINICAL_TRIALS_REGISTRY]
TOTAL EXTRACTED9
RECRUITING STATUS1
COMPLETED RUNS7
REGISTRY & PHASE
TESTED CONDITION
STUDY TITLE & LIFECYCLE TIMELINES
STATUS
P-2NCT07009860
Alcohol Liver Disease
N=100Est. Finish: 2027-08-31
RESTORE TRIAL: A Phase 2 Study Evaluating the Efficacy and Safety of Pemvidutide in the Treatment of Alcohol-Associated Liver Disease (ALD)
recruiting
P-2NCT06987513
Alcohol Use Disorder (AUD)
N=100Est. Finish: 2026-06
RECLAIM STUDY: A Phase 2 Evaluating the Efficacy and Safety of Pemvidutide in the Treatment of Alcohol Use Disorder (AUD) in Subjects With Obesity or Overweight
active not recruiting
P-2NCT05989711
Non-Alcoholic Steatohepatitis (NASH)
N=212Est. Finish: 2025-11-25
IMPACT TRIAL: Efficacy and Safety of Pemvidutide in Subjects With Nonalcoholic Steatohepatitis (NASH)
completed
P-2NCT05295875
Obesity/Overweight
N=391Est. Finish: 2023-09-28
Efficacy and Safety of ALT-801 in the Treatment of Obesity
completed
P-1NCT05134662
Type 2 Diabetes
N=55Est. Finish: 2023-03-09
ALT-801 in Overweight and Obese Subjects With Type 2 Diabetes Mellitus (T2DM)
completed
P-1NCT04972396
NASH - Nonalcoholic Steatohepatitis
N=40Est. Finish: 2022-05-15
Pemvidutide (ALT-801) DDI Study in Healthy Volunteers
completed
P-1NCT05006885
Non-Alcoholic Fatty Liver Disease
N=95Est. Finish: 2022-08-17
ALT-801 in Diabetic and Non-Diabetic Overweight and Obese Subjects With Non-alcoholic Fatty Liver Disease (NAFLD)
completed
P-1NCT05292911
Non-Alcoholic Fatty Liver Disease
N=64Est. Finish: 2022-10-31
Extension of ALT-801 in Diabetic and Non-Diabetic Overweight and Obese Subjects With (NAFLD)
completed
P-1NCT04561245
ObesityNonalcoholic Steatohepatitis
N=100Est. Finish: 2021-10-29
ALT-801 (Pemvidutide) in Healthy Overweight and Obese Volunteers to Study Safety and Tolerability
completed
[BIOCHEMICAL_STRUCTURE_REGISTRY]
MOLECULAR FORMULAC178H270N38O53
MOLECULAR WEIGHT3790 g/mol
PARTITION (XLogP)-7.4
H-BOND DONORS51
H-BOND ACCEPTORS57
COMPLEXITY SCORE8720
SMILES (CANONICAL / ISOMERIC)
CC[C@H](C)[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N)NC(=O)[C@H](CC3=CC=CC=C3)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCCCNC(=O)[C@@H]4[C@H]([C@@H]([C@H]([C@@H](O4)OCCCCCCCCCCCCCCCCCC(=O)O)O)O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC5=CC=C(C=C5)O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC6=CC=C(C=C6)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC7=CC=CC=C7)NC(=O)[C@H]([C@@H](C)O)NC(=O)CNC(=O)[C@H](CCC(=O)N)NC(=O)C(C)(C)NC(=O)[C@H](CC8=CNC=N8)N
INCHI KEYPNRXPXQSTNKDJB-VGUJMDGVSA-N
2D_DEPICTION_FALLBACK